CYRX - Cryoport, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
9.18
+0.56 (+6.50%)
As of 3:56PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close8.62
Open8.62
Bid9.17 x 1100
Ask9.20 x 900
Day's Range8.62 - 9.23
52 Week Range6.66 - 16.88
Volume203,549
Avg. Volume195,090
Market Cap268.42M
Beta (3Y Monthly)1.70
PE Ratio (TTM)N/A
EPS (TTM)-0.35
Earnings DateJun 29, 2017 - Jun 30, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.40
Trade prices are not sourced from all markets
  • Dacos A/S Partners with Cryoport to Offer Full Suite of Temperature-Controlled Logistics Solutions to Global Client Base
    PR Newswire3 days ago

    Dacos A/S Partners with Cryoport to Offer Full Suite of Temperature-Controlled Logistics Solutions to Global Client Base

    IRVINE, Calif., Jan. 14, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Cryoport" or "the Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced it has partnered with Dacos A/S ("Dacos"), a high-tech production company of life sciences products with headquarters in Denmark, to deliver end-to-end temperature-controlled logistics solutions to Dacos' global client base of biopharmaceutical companies.

  • Cryoport Appoints Daniel M. Hancock to Board of Directors
    PR Newswire10 days ago

    Cryoport Appoints Daniel M. Hancock to Board of Directors

    IRVINE, Calif., Jan. 7, 2019 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, is pleased to announce the appointment of Daniel M. (Dan) Hancock to its Board of Directors. Mr. Hancock's appointment adds extensive physics knowledge, engineering and innovation experience, business acumen and leadership to the Board of Directors. Mr. Hancock will serve on the Audit Committee, chaired by Richard Berman, Esq.

  • Cryoport Announces $25 Million Investment from Petrichor Healthcare Capital Management
    PR Newswirelast month

    Cryoport Announces $25 Million Investment from Petrichor Healthcare Capital Management

    IRVINE, Calif., Dec. 17, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or "the Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced the closing of a $25 million investment from Petrichor Healthcare Capital Management ("Petrichor"). Under the terms of the investment, Petrichor purchased $10 million of Cryoport common shares at a price per share of $10.00.  In addition, Petrichor has funded a $15 million note, which is convertible into Cryoport common shares at a price per share of $13.11, based upon a 20.0% premium to the 15-day VWAP immediately prior to closing.

  • GlobeNewswirelast month

    Consolidated Research: 2018 Summary Expectations for IRHYTHM TECH, ON Semiconductor, CryoPort, Celcuity, InnerWorkings, and AgroFresh Solutions — Fundamental Analysis, Key Performance Indications

    NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Does Cryoport Inc (NASDAQ:CYRX) Have A Volatile Share Price?
    Simply Wall St.2 months ago

    Does Cryoport Inc (NASDAQ:CYRX) Have A Volatile Share Price?

    If you own shares in Cryoport Inc (NASDAQ:CYRX) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of Read More...

  • Zacks Small Cap Research2 months ago

    CYRX: Q3 Another Very Strong Quarter With New Records in Several Categories. Operating Leverage Continues To Solidify

    In addition, the 37 new clinical trials added in the period were a record high and operating expenses as a percentage of revenue were a record low. The topline was well-ahead of our number, as was total biopharma and reproductive medicine. Total revenue crushed the prior best (Q2: $4.6M) by 14% but that actually may not be the most encouraging sign that CYRX may be able to reach profitability in the not-too-distant future.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CYRX earnings conference call or presentation 8-Nov-18 9:30pm GMT

    Q3 2018 Cryoport Inc Earnings Call

  • Cryoport Revenue Grows 76% for Third Quarter 2018; 91% Growth in Biopharma
    PR Newswire2 months ago

    Cryoport Revenue Grows 76% for Third Quarter 2018; 91% Growth in Biopharma

    295 Regenerative Medicine Clinical Trials Now Supported by Cryoport; 38 Programs in Phase III Revenue from Commercialized CAR-T Therapies Continues to Ramp IRVINE, Calif. , Nov. 8, 2018 /PRNewswire/ -- ...

  • Cryoport to Report Third Quarter 2018 Financial Results on November 8th, 2018
    PR Newswire3 months ago

    Cryoport to Report Third Quarter 2018 Financial Results on November 8th, 2018

    IRVINE, Calif. , Oct. 30, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the world's leading temperature controlled logistics company ...

  • Cryoport Celebrates Grand Opening of its Global Logistics Center In New Jersey with Ribbon Cutting Ceremony
    PR Newswire3 months ago

    Cryoport Celebrates Grand Opening of its Global Logistics Center In New Jersey with Ribbon Cutting Ceremony

    IRVINE, Calif., Oct. 23, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today unveiled its newest Global Logistics Center, based in Livingston, New Jersey with a ribbon-cutting ceremony attended by several of Cryoport's clients, local dignitaries and business partners. Cryoport's newest state-of-the-art Global Logistics Center is located in a strategic life sciences hub and provides an important addition to Cryoport's logistics network, which allows the Company to more effectively support its biopharma clients.

  • GlobeNewswire3 months ago

    Market Trends Toward New Normal in CryoPort, The J. M. Smucker, Accenture, Albemarle, The Allstate, and Huami — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Oct. 22, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Simply Wall St.3 months ago

    What Does Cryoport Inc’s (NASDAQ:CYRX) Ownership Structure Look Like?

    If you want to know who really controls Cryoport Inc (NASDAQ:CYRX), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock in bigger Read More...

  • Business Wire3 months ago

    Be The Match BioTherapies® and Cryoport Announce Strategic Partnership to Deliver Integrated End-to-End Supply Chain Services to the Cell and Gene Therapy Industry

    Be The Match BioTherapies, an organization offering integrated systems and software to manage the collection and delivery of cellular therapies, and Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced a strategic partnership to deliver end-to-end supply chain services to the cell and gene therapy industry. The collaboration will support both organizations’ efforts to standardize critical elements of the cell therapy supply chain, as well as processes in apheresis and transplant center networks. An important part of the agreement is to integrate Be The Match BioTherapies’ MatchSource® cell therapy supply chain software and Cryoport’s Cryoportal™ Logistics Management Platform.

  • Be The Match BioTherapies® and Cryoport Announce Strategic Partnership to Deliver Integrated End-to-End Supply Chain Services to the Cell and Gene Therapy Industry
    PR Newswire3 months ago

    Be The Match BioTherapies® and Cryoport Announce Strategic Partnership to Deliver Integrated End-to-End Supply Chain Services to the Cell and Gene Therapy Industry

    MINNEAPOLIS, Minn. and IRVINE, Calif., Oct. 3, 2018 /PRNewswire/ -- Be The Match BioTherapies, an organization offering integrated systems and software to manage the collection and delivery of cellular therapies, and Cryoport, Inc. (NASDAQ: CYRX, CYRXW), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced a strategic partnership to deliver end-to-end supply chain services to the cell and gene therapy industry. The collaboration will support both organizations' efforts to standardize critical elements of the cell therapy supply chain, as well as processes in apheresis and transplant center networks. An important part of the agreement is to integrate Be The Match BioTherapies' MatchSource® cell therapy supply chain software and Cryoport's Cryoportal™ Logistics Management Platform.

  • What Investors Should Know About Cryoport Inc’s (NASDAQ:CYRX) Financial Strength
    Simply Wall St.4 months ago

    What Investors Should Know About Cryoport Inc’s (NASDAQ:CYRX) Financial Strength

    The direct benefit for Cryoport Inc (NASDAQ:CYRX), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off isRead More...

  • Zacks Small Cap Research5 months ago

    CYRX: Commercial Support and Clinical Trial Revenue Ramping. Commercial Support Pipeline Increasing Long-Term Value

    The regular increase of clinical trial related revenue has been (and continues to be) the product of regular growth in the number of clinical trials that CYRX supports - including the number of phase III trials.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of CYRX earnings conference call or presentation 9-Aug-18 8:30pm GMT

    Q2 2018 Cryoport Inc Earnings Call

  • Cryoport Revenue Grows 59% for Second Quarter 2018; 73% in Biopharma
    PR Newswire5 months ago

    Cryoport Revenue Grows 59% for Second Quarter 2018; 73% in Biopharma

    Revenue from Approved CAR-T Therapies Continues to Ramp Record 258 Clinical Trials Now Supported by Cryoport, with 34 Programs in Phase III IRVINE, Calif. , Aug. 9, 2018 /PRNewswire/ -- Cryoport, Inc. ...

  • Cryoport Launches CryoStork℠ Insurance to Support IVF Logistics Solutions
    PR Newswire5 months ago

    Cryoport Launches CryoStork℠ Insurance to Support IVF Logistics Solutions

    IRVINE, Calif., Aug. 7, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced the upcoming launch of CryoStork℠ Insurance, which is designed to better serve intended parents and is also in response to the rise in demand for assisted reproductive medicine. With many couples struggling with infertility and approximately 6.7 million women in the U.S. alone unable to bear a child as reported by the American Society for Reproductive Medicine (ASRM), Cryoport is proud to now expand its offerings for the reproductive medicine market to include insurance options. CryoStork℠ Insurance will be offered exclusively to Cryoport clients and to the patients at the more than 400 clinics working with Cryoport.

  • Cryoport to Report Second Quarter 2018 Financial Results on August 9th, 2018
    PR Newswire6 months ago

    Cryoport to Report Second Quarter 2018 Financial Results on August 9th, 2018

    IRVINE, Calif. , Aug. 1, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the world's leading temperature controlled logistics company ...

  • Cryoport Partners with World Courier to Provide Best-In-Class Logistics Platform for Global Cell and Gene Therapy Market
    PR Newswire6 months ago

    Cryoport Partners with World Courier to Provide Best-In-Class Logistics Platform for Global Cell and Gene Therapy Market

    IRVINE, Calif., July 16, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), today announced that World Courier, a part of AmerisourceBergen, will integrate Cryoport's full suite of temperature-controlled solutions into its global network.  This integrated platform offers complete Chain of Compliance™ solutions for biopharmaceutical companies, ensuring full traceability of equipment, processes, and handling of cell and gene therapies while in transit. This will result in an offering of Cryoport's Chain of Compliance™ solutions to World Courier clients.

  • Cryoport Delivers Biological Samples for International Space Station; Rocket Launched Today Arrives at International Space Station on Monday
    PR Newswire7 months ago

    Cryoport Delivers Biological Samples for International Space Station; Rocket Launched Today Arrives at International Space Station on Monday

    IRVINE, Calif., June 29, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading temperature controlled logistics company dedicated to the life sciences industry, announced that biological samples transported by Cryoport were launched today at 5:42 am EDT on SpaceX's Falcon 9 rocket which took off from Cape Canaveral in Florida to the International Space Station (ISS). On May 25, 2018, Cryoport managed the transportation of biological samples, specifically isolated primary human mononuclear cells from blood donors, from the University of Zurich to the Kennedy Space Center.

  • When Should You Buy Cryoport Inc (NASDAQ:CYRX)?
    Simply Wall St.7 months ago

    When Should You Buy Cryoport Inc (NASDAQ:CYRX)?

    Cryoport Inc (NASDAQ:CYRX), a medical equipment company based in United States, received a lot of attention from a substantial price increase on the NasdaqCM over the last few months. AsRead More...

  • Cryoport Set to Join Russell 3000 Index and Russell 2000 Index
    PR Newswire7 months ago

    Cryoport Set to Join Russell 3000 Index and Russell 2000 Index

    IRVINE, Calif., June 11, 2018 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Cryoport" or the "Company"), the global leader in temperature-controlled logistics dedicated to the life sciences industry, today announced it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective after the US market opens on June 25th, according to a preliminary list of additions posted June 8th. Annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of May 11th, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.